Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) Return on Invested Capital (2023 - 2025)

Historic Return on Invested Capital for 60 Degrees Pharmaceuticals (SXTPW) over the last 3 years, with Q3 2025 value amounting to 1.89%.

  • 60 Degrees Pharmaceuticals' Return on Invested Capital fell 100.0% to 1.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.89%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 1.65% for FY2024, which is 23100.0% down from last year.
  • According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' Return on Invested Capital is 1.89%, which was down 100.0% from 1.98% recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Return on Invested Capital's 5-year high stood at 0.23% during Q2 2023, with a 5-year trough of 2.2% in Q1 2025.
  • Over the past 3 years, 60 Degrees Pharmaceuticals' median Return on Invested Capital value was 1.6% (recorded in 2024), while the average stood at 1.22%.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first tumbled by -18300bps in 2024, then crashed by -100bps in 2025.
  • Quarter analysis of 3 years shows 60 Degrees Pharmaceuticals' Return on Invested Capital stood at 0.65% in 2023, then plummeted by -164bps to 1.73% in 2024, then decreased by -10bps to 1.89% in 2025.
  • Its Return on Invested Capital was 1.89% in Q3 2025, compared to 1.98% in Q2 2025 and 2.2% in Q1 2025.